Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 447

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 447
---
 which include five trusts for the benefit of the family of our founder Johnnie R. Williams, Sr., as well as MIRALOGX,
collectively own in excess of 70% of our issued and outstanding common stock. Brian McNulty acts as the trustee for such trusts. Our
officers and directors also own shares of our common stock. Therefore, these entities and individuals could influence the outcome of
matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions.

Sales
of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress
the market price of our common stock.

Sales
of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur as a result
of our utilization of a universal shelf registration statement or otherwise could depress the market price of our common stock and impair
our ability to raise capital through the sale of additional equity securities. Notably, a large number of shares of our common stock
held by founding stockholders of our company have been registered for public resale and could be sold on the public market, depressing
our stock price. Moreover, we cannot in general predict the effect that future sales of our common stock or the market perception that
we are permitted to sell a significant number of our securities would have on the market price of our common stock.

40

The
requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract
and retain executive management and qualified board members.

As
a reporting issuer, we are subject to the reporting requirements of applicable securities legislation of the jurisdiction in which it
is a reporting issuer, the listing requirements of Nasdaq and other applicable securities rules and regulations. Compliance with these
rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or
costly and increase demand on its systems and resources. Applicable securities laws will require us to, among other things, file certain
annual and quarterly reports with respect to its business and results of operations. In addition, applicable securities laws require
us to, among other things, maintain effective disclosure controls and procedures and internal control over financial reporting.

In
order to maintain and, if required, improve its disclosure controls and procedures and internal control over financial reporting to meet
this standard, significant resources and management oversight are required. Specifically, due to the increasing complexity of its transactions,
it